Endocrine response in rabbits immunized with native versus deglycosylated porcine zona pellucida antigens.
Previous studies evaluating porcine zona pellucida antigens for immunocontraceptive purposes have in some cases revealed altered ovarian function in association with antibody response. This study was undertaken in an attempt to identify zona immunogens that do not cause adverse endocrine effects. To this end, we investigated the effects of highly purified preparations of native and deglycosylated pig zona pellucida antigens on ovarian function and immune response in the rabbit. Thirty female rabbits were immunized, 5 per group, with 100 micrograms each of either 1) SIZP, solubilized isolated zonae pellucidae; 2) ZP3, a purified porcine zona preparation containing the two principle glycoproteins, ZP3 alpha and ZP3 beta, endo-beta-galactosidase-digested ZP3 glycoproteins (approximately 30% deglycosylated) termed 3) ZP3 alpha/EBGD and 4) ZP3 beta/EBGD; and chemically deglycosylated ZP3 alpha and ZP3 beta (greater than or equal to 92% deglycosylated), termed 5) ZP3 alpha/DG and 6) ZP3 beta/DG. Rabbits injected with saline (n = 2) or Freund's adjuvant alone (n = 3) served as controls. Serum LH, FSH, estradiol, and progesterone were measured at 5-day intervals during seven 20-day cycles of hCG-induced pseudopregnancy over 42 wk. Anti-ZP3 titers, determined by RIA, developed in all treatment groups and correlated directly with carbohydrate content. Animals immunized with SIZP, ZP3, and ZP3 beta/EBGD showed a significant elevation of LH and FSH and a significant decline of peak progesterone levels by the fourth pseudopregnancy cycle. In contrast, animals immunized with ZP3 alpha/EBGD, ZP3 alpha/DG, and ZP3 beta/DG showed no significant elevations of gonadotropins and continued to display cyclic progesterone secretion in response to hCG.(ABSTRACT TRUNCATED AT 250 WORDS)
Keenan
J A
JA
Department of Obstetrics & Gynecology, Wayne State University School of Medicine, C.S. Mott Center for Human Growth and Development, Detroit, Michigan 48201.
Sacco
A G
AG
Subramanian
M G
MG
Kruger
M
M
Yurewicz
E C
EC
Moghissi
K S
KS
D000818:Animals; D000917:Antibody Formation; D000941:Antigens / Q000008:administration & dosage*; D003269:Contraception, Immunologic / Q000009:adverse effects; D004527:Egg Proteins; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006023:Glycoproteins / Q000276:immunology*; D006031:Glycosylation; D006728:Hormones / Q000097:blood*; D007114:Immunization; D007986:Luteinizing Hormone / Q000097:blood; D008562:Membrane Glycoproteins; D010053:Ovary / Q000502:physiology; D011374:Progesterone / Q000097:blood; D011817:Rabbits; D011956:Receptors, Cell Surface; D013552:Swine; D015044:Zona Pellucida / Q000276:immunology*; D000072216:Zona Pellucida Glycoproteins
D000941:Antigens; D004527:Egg Proteins; D006023:Glycoproteins; D006728:Hormones; D008562:Membrane Glycoproteins; D011956:Receptors, Cell Surface; C000606517:ZP3 protein, human; D000072216:Zona Pellucida Glycoproteins; D011374:Progesterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone